a leading life science company and member of The RNAi Consortium (TRC), proudly
welcomes the Memorial Sloan-Kettering Cancer Center to the RNAi
Partnership Program. The RNAi Partnership Program provides new members with
access to cutting-edge products in Sigma-Aldrich's functional genomics portfolio,
including shRNA libraries developed by TRC targeting more than 15,000 human
genes and 15,000 mouse genes.
"We are excited to become a member of the RNAi Partnership Program and
we look forward to productive collaborations with our colleagues at Sigma- Aldrich,"
said Dr. Hakim Djaballah, Director of the High Throughput Screening Core Facility.
"Many of our researchers are interested in targeted gene knockdown on an
individual or gene-focused basis, as well as a genome-wide scale for which we
are fully equipped. Access to Sigma-Aldrich's MISSION shRNA libraries will greatly
enhance our current gene scanning capabilities and will enable us to discover
and validate cancer-causing genes and pathways which will hopefully lead to
novel approaches to therapeutic intervention for cancer patients."
Through the RNAi Partnership Program, Sigma-Aldrich aims to establish collaborations
with select academic institutions. The company advances functional genomics
research by aiding academic researchers with early exposure to emerging new
techniques, a broad portfolio of intellectual property, and special partnership
pricing on Sigma-Aldrich's extensive RNAi product lines. Existing members of
the RNAi Partnership Program include The Cleveland Clinic, The Harvard Stem
Cell Institute, Washington University of St. Louis, Princeton University, The
Wistar Institute, and Rutgers University. These members enjoy unique access
to cutting-edge RNAi tools for the study of basic gene function and the underlying
causes of disease.
"Sigma-Aldrich is committed to expanding our collaborative relationships
with prestigious institutions like the Memorial-Sloan Kettering Cancer Center,"
said Tim Fleming, Sigma-Aldrich's Director of Global Commercial Marketing for
Life Sciences. "We look forward to the success of the Memorial Sloan-Kettering
researchers utilizing our leading MISSION library, and will continue to look
for innovative ways to accelerate our partners' success."
Sigma-Aldrich has recently made major commitments to the rapidly developing
area of RNAi. This began with the establishment of research collaborations with
the RNAi Consortium, followed by licensing agreements with MIT to make and sell
the shRNA libraries developed by TRC and, subsequently, the introduction of
Sigma-Aldrich's MISSION TRC shRNA libraries. Additional agreements with Alnylam,
Benitec and Oxford BioMedica provide Sigma-Aldrich with a major intellectual
property portfolio in RNAi.
For more information about The RNAi Consortium and participating members,
please visit http://www.broad.mit.edu/rnai/trc.